relapsed refractory multiple myeloma
Showing 1 - 5 of 5
Relapsed Refractory Multiple Myeloma Trial (REGN5458, Elotuzumab, Pomalidomide)
Not yet recruiting
- Relapsed Refractory Multiple Myeloma
- REGN5458
- +3 more
- (no location specified)
Feb 6, 2023
Relapsed Refractory Multiple Myeloma Trial in India (Drug: Carfilzomib + Dexamethasone, Drug: Carfilzomib + Lenalidomide +
Active, not recruiting
- Relapsed Refractory Multiple Myeloma
- Drug: Carfilzomib + Dexamethasone
- Drug: Carfilzomib + Lenalidomide + Dexamethasone
-
Hyderabad, Andhra Pradesh, India
- +16 more
Dec 13, 2022
Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphocytic Leukemia Trial in Boston (Antithymocyte Globulin,
Active, not recruiting
- Acute Myeloid Leukemia
- +6 more
- Antithymocyte Globulin
- Clofarabine
-
Boston, Massachusetts
- +1 more
Jan 25, 2022
Relapsed Refractory Multiple Myeloma Trial in United States (Abemaciclib, dexamethasone, ixazomib, pomalidomide, Enasidenib,
Recruiting
- Relapsed Refractory Multiple Myeloma
- Abemaciclib, dexamethasone, ixazomib, pomalidomide
- +7 more
-
Phoenix, Arizona
- +16 more
Sep 9, 2021
Relapsed Refractory Multiple Myeloma Trial in United States (NEXI-002 T Cells)
Recruiting
- Relapsed Refractory Multiple Myeloma
- NEXI-002 T Cells
-
Duarte, California
- +5 more
Dec 1, 2020